56 results about "SIGLEC" patented technology

The invention relates to the technical field of biomedical materials, in particular to engineered small extracellular vesicle hydrogel enriched with PD-L1 and Siglec-15 as well as a preparation method and application of the engineered small extracellular vesicle hydrogel. The engineering small extracellular vesicle hydrogel is enriched with PD-L1 and Siglec-15 at the same time, the engineering small extracellular vesicle hydrogel comprises a hydrogel base body and PDL1-Siglec15-sEVs loaded in the hydrogel base body, and the PDL1-Siglec15-sEVs are small extracellular vesicles with the PD-L1 and the Siglec-15 in an overexpression mode. Compared with natural small extracellular vesicles and a traditional wound surface treatment strategy, the engineered small extracellular vesicle hydrogel has the advantages that PD-L1 and Siglec-15 can be enriched in the vesicles, so that more accurate immune microenvironment regulation and control can be realized on the local part of a wound surface, excessive inflammatory response is moderately inhibited, phenotype transformation of macrophages to be beneficial to tissue regeneration is promoted, and the wound surface treatment effect is improved. The hydrogel is used as a carrier and can provide a moist healing environment and a three-dimensional scaffold structure, so that the residence time of the engineered small extracellular vesicles on the local wound surface is remarkably prolonged, and slow release is realized.

The present invention provides anti-Siglec-15 antibodies and antigen-binding fragments thereof as well as isolated nucleic acids, vectors, engineered cells, formulations thereof, and methods of use thereof for treating diseases including cancer and bone disease in a human subject. The invention is further directed to bispecific and multispecific antibodies, antibody-drug conjugates and chimeric antigen receptors derived from the anti-Siglec-15 antibodies and fragments thereof.

Provided herein are antibodies and antibody fragments relating to SIGLEC-8 and CD117. Provided herein are methods and compositions relating to SIGLEC-8 and / or CD117 libraries having nucleic acids encoding for a scaffold comprising a SIGLEC-8 and / or CD117 domain. SIGLEC-8 and / or CD117 libraries described herein encode for immunoglobulins such as antibodies.

Provided herein are anti-Siglec-10 and Siglec-8 antibody compositions and combinations thereof, and their use in the treatment of neurodegenerative diseases.

The present application relates to the technical field of biomedical materials, in particular to an engineered small extracellular vesicle hydrogel enriched with PD-L1 and Siglec-15, and a preparation method and application thereof. The engineered small extracellular vesicle hydrogel is simultaneously enriched with PD-L1 and Siglec-15, and comprises a hydrogel matrix and PDL1-Siglec15-sEVs loaded in the hydrogel matrix, wherein the PDL1-Siglec15-sEVs are small extracellular vesicles overexpressing PD-L1 and Siglec-15. Compared with natural small extracellular vesicles and traditional wound treatment strategies, the engineered small extracellular vesicle hydrogel of the present application can realize more precise immune microenvironment regulation at the local wound by enriching PD-L1 and Siglec-15 in the vesicles, moderately inhibit excessive inflammatory response, promote the phenotype transformation of macrophages to a phenotype conducive to tissue regeneration, help smooth transition from the inflammatory stage to the proliferation and reconstruction stage, and the hydrogel as a carrier can provide a moist healing environment and a three-dimensional scaffold structure, significantly prolong the residence time of the engineered small extracellular vesicles at the local wound, and realize slow release.

The invention belongs to the technical field of biological pharmacy, and particularly discloses a Siglec-15 affinity peptide and application thereof. According to the invention, a phage display heptapeptide library high-throughput screening technology is adopted, Siglec-15 affinity peptide 7-8 is obtained through multiple rounds of screening, and the Siglec-15 affinity peptide 7-8 is optimized and modified to obtain a reversed sequence flip peptide d-7-8. Experimental results show that the Siglec-15 affinity peptide can be used for affinity of Siglec-15 protein and blocking the interaction between Siglec-15 and a ligand Sialyl-Tn of Siglec-15, so that the anti-tumor effect is achieved; an in-vitro cell level experiment shows that the Siglec-15 affinity peptide has a relieving effect on inhibition of Siglec-15 on CD8 + T cell proliferation, has an obvious immune activation effect, does not have obvious toxic or side effects, can be used for preparing an anti-tumor drug or a detection reagent taking Siglec-15 as a target spot, and has a relatively good medical application prospect.

The present invention provides anti-Siglec-9 antibodies and antigen-binding fragments thereof as well as isolated nucleic acids, vectors, engineered cells, formulations thereof, and methods of use thereof for treating diseases including cancer and bone disease in a human subject. The invention is further directed to bispecific and multispecific antibodies, antibody-drug conjugates and chimeric antigen receptors derived from the anti-Siglec-9 antibodies and fragments thereof.

The present invention provides anti-Siglec-9 antibodies and antigen-binding fragments thereof as well as isolated nucleic acids, vectors, engineered cells, formulations thereof, and methods of use thereof for treating diseases including cancer and bone disease in a human subject. The invention is further directed to bispecific and multispecific antibodies, antibody-drug conjugates and chimeric antigen receptors derived from the anti-Siglec-9 antibodies and fragments thereof.

The present invention provides compositions comprising anti-Siglec antibodies and nucleic acid molecules encoding the same, and methods for treating or preventing a disease or disorder using the same.

The invention discloses a dual-regulation pharmaceutical composition for sepsis treatment, a preparation method and application, and belongs to the technical field of biological medicine, and the pharmaceutical composition comprises doxorubicin liposome, all-trans retinoic acid phospholipid complex nanoparticles and antibiotics. Preferably, the doxorubicin liposome is prepared from the sialic acid modified doxorubicin liposome, the sialic acid modified all-trans retinoic acid phospholipid compound nanoparticles and meropenem. Dynamic monitoring of myeloid-derived suppressor cells MDSCs and sialic acid binding immunoglobulin type lectin-E (SiglecE) positively expressed myeloid-derived suppressor cells, namely SiglecE + MDSCs cell subsets, in the middle and later periods of sepsis is used as an evaluation index of the immunosuppression state, and dual regulation and control of sepsis acute inflammation and immunosuppression are achieved. The method has remarkable advantages in the aspects of increasing the survival rate, precisely targeting immunosuppression, improving the drug delivery efficiency and the like, and a brand new solution is provided for clinical treatment of sepsis.

The application discloses a nanobody against sialic acid-binding immunoglobulin-like lectin 15 and a related biomaterial and application thereof, and belongs to the technical field of immunotherapy biological medicine. The nanobody against sialic acid-binding immunoglobulin-like lectin 15 or an antigen-binding fragment thereof provided by the application comprises three complementarity determining regions CDR1, CDR2 and CDR3, the nanobody is S1, the amino acid sequence of CDR1 of the S1 is SEQ ID No. 6, the amino acid sequence of CDR2 of the S1 is SEQ ID No. 7, and the amino acid sequence of CDR3 of the S1 is SEQ ID No. 8. The nanobody against sialic acid-binding immunoglobulin-like lectin 15 provided by the application can play a role in the development of a therapeutic drug for a cancer patient with high expression of Siglec-15.

The application of the biomarker combination in the preparation of a drug for fulminant myocarditis belongs to the field of drugs. The application is characterized in that the biomarker combination comprises Siglec-5; the biomarker combination is further selected from the group consisting of sST2, PAI-1, Siglec-5, CD163, CD40, P-Cadherin, CD14, CTLA4. The application finds that the expression of the biomarker in the plasma of a patient with fulminant myocarditis is increased, and confirms the role of the biomarker as a drug target in relieving and / or improving fulminant myocarditis. The level of the biomarker can be controlled by a drug, the diagnosis and subsequent treatment of the disease can be more intensified, and the biomarker has great application value in clinical practice.

The present invention provides compositions comprising anti-Siglec-10 antibodies and nucleic acid molecules encoding the same, and methods for treating or preventing a disease or disorder using the same.

This invention provides a kit and detection method for detecting the Siglec fusion mutation gene and the GBS pathogenic gene. It is used for rapid combined detection of the Siglec5 / 14 fusion mutation gene, a preterm birth susceptibility gene, and the GBS pathogenic gene. It can effectively assess the risk of gynecological reproductive tract infections, preterm birth in pregnant women, and infection in newborns. It solves the problem that existing kits only detect the conditionally pathogenic bacteria and have poor specificity for disease association. The detection using this kit is faster and more sensitive. The detection process is closed-loop, avoiding the additional operation of electrophoresis differentiation. It is low-cost and easy to promote.

To provide pigs that exhibit resistance to porcine reproductive respiratory syndrome virus (PRRSV). [Solution] This disclosure relates to a genetically modified pig in which at least one allele of the SIGLEC-1 gene is inactivated and / or at least one allele of the CD163 gene is inactivated. A genetically modified pig in which both alleles of the SIGLEC-1 gene and / or both alleles of the CD163 gene are inactivated is resistant to porcine reproductive respiratory syndrome virus (PRRSV). Methods for producing such transgenic pigs are also provided.

Anti-Siglec-9 antibody molecules or binding fragments thereof are disclosed. These anti-Siglec-9 antibody molecules or binding fragments can be used to treat cancer, acute or chronic hepatitis B.

Undesired mast cell activities are linked with various diseases or disorders, such as allergies, inflammatory diseases, autoimmune diseases, and cancers. There remains a need for new and improved therapeutics (e.g., for mast cell associated diseases or disorders) that can target c-Kit and / or siglec-6. Disclosed herein are molecules, such as antibodies and antibody fragments, capable of binding to c-Kit and / or siglec-6.

The invention discloses a CDR region of a nano antibody targeting Siglec-9, and a preparation method of the CDR region of the nano antibody targeting Siglec-9. The invention also discloses a nano antibody, and the nano antibody comprises the CDR region of the nano antibody targeting Siglec-9. The invention also discloses an antibody for targeting the Siglec-9. The invention further discloses the antibody for targeting the Siglec-9. The invention also discloses a polynucleotide, an expression vector, a host cell and an antibody conjugate. The invention also discloses a CDR region of the nano antibody targeting Siglec-9, the nano antibody, the antibody targeting Siglec-9, and an application of the antibody conjugate. The invention also discloses a pharmaceutical composition. The nano antibody and the Siglec-9 targeting antibody have specific recognition and binding performance on Siglec-9G protein, can target Siglec-9, and can be used for preparing reagents, kits or drugs for diagnosing, treating and / or preventing Siglec-9 related diseases.

Inhibiting mast cell activation by binding sialic acid-binding immunoglobulin-like lectin-9 (Siglec-9) is described. Inhibiting mast cell activation by binding Siglec-9 can be used to treat mast-cell associated inflammatory disorders, such as allergic diseases, rheumatoid arthritis, and mastocytosis.

This invention discloses a Siglec15-specific blocking peptide and its applications, relating to the field of biopharmaceutical technology. The specific blocking peptide is the following polypeptide or its modified form: (1) a polypeptide with the amino acid sequence shown in SEQ ID NO: 2; (2) a polypeptide with the amino acid sequence shown in SEQ ID NO: 21. This invention provides a Siglec-15-specific blocking peptide, which has a strong affinity for Siglec-15 protein, can efficiently block the interaction between Siglec-15 and its ligand Sialyl-Tn, and exhibits good serum stability and low toxicity; it also provides polypeptide probes, related reagents, drugs, and applications of this blocking peptide.

The present invention provides natural killer engagers specific for activating natural killer cells through binding to Siglec-7, and nucleic acid molecules encoding the same, and methods for treating or preventing a disease or disorder using the same.

The present invention relates to a pharmaceutical composition for preventing or treating sicca syndrome, comprising a recombinant antisemaphorin 4D blocking antibody as an active ingredient.

The present disclosure provides compositions for inhibiting interaction of Siglec-5 with its cognate ligand on cancer cells and their use as checkpoint inhibitors in the treatment of neoplastic disorders. A method for the treatment and / or prevention of a cancer that expresses a Siglec-5 ligand in a subject is provided comprising administering to the subject a molecule that inhibits the interaction between Siglec-5 and a Siglec-5 ligand expressed on the cancer cell. In some aspects, the subject is identified as having a cancer expressing a Siglec-5 ligand. Preferably, the molecule is a monoclonal antibody against Siglec-5.

An anti-Siglec-15 antibody and a use thereof, specifically, an isolated anti-Siglec-15 antibody or antigen-binding fragment thereof, an expression vector and host cell for expressing the antibody or antigen-binding fragment thereof, and a use of the antibody or antigen-binding fragment and a pharmaceutical composition containing the antibody or antigen-binding fragment thereof, and a use of the pharmaceutical composition.

The application provides an anti-Siglec-6 nanobody and a preparation method and application thereof, and belongs to the technical field of biological medicines. The specific nanobody of anti-Siglec-6 is screened from a double-peak camel VHH immune library, and can specifically combine with the Siglec-6 antigen. ‑14 ~10 ‑11 M order of magnitude, and the affinity is high. The nanobody can specifically combine with the Siglec-6 of human origin, can be used for preparing medicines for preventing or treating various diseases such as acute myeloid leukemia, allergy and inflammation, and has a wide application prospect.

The invention provides a rheumatoid arthritis biomarker as well as a screening method, application and a kit, and the rheumatoid arthritis biomarker is AXL + SIGLEC-6 + dendritic cells (AS DC for short). According to the invention, AS DC can be used as a specific marker for evaluating the disease activity of RA for the first time, and the disease activity of RA can be effectively measured.

The invention provides a preparation method of in-vitro sialic acid-calcium ion self-assembled nanoparticles (SA-CaNPs), and relates to the technical fields of organic chemistry, biological medicine nanometer, molecular biology and the like. The nanoparticles are formed by self-assembly of sialic acid derivatives (preferably N-acetylneuraminic acid) and divalent calcium ions, and the particle size is 300-500 nm. The preparation method comprises the following steps: mixing a sialic acid solution with a calcium chloride solution, stirring and self-assembling without an organic solvent or a surfactant. The SA in the particle can be naturally combined with a Siglecc receptor highly expressed by a tumor / brain, so that the active targeting property of the medicine is expected to be improved; ca < 2 + > is dissociated in a lysosome acidic environment (pH 5.0), and can respond to release of drugs. The nanoparticles formed by self-assembly of the two have wide application prospects in the field of drug loading.

The invention relates to the technical field of biological medicines, in particular to a responsive RNA (Ribonucleic Acid) delivery system for brain glioma as well as a preparation method and application of the responsive RNA delivery system. Through fusion of blood-brain barrier penetrating peptide ANG-2 mediated cross-blood-brain barrier delivery and combination of Siglec-15 mediated immune targeting recognition, a dual targeting mechanism is constructed, a delivery system can be guided to accurately recognize a glioma focus, the enrichment amount of the delivery system in a focus area is remarkably increased, a foundation is laid for playing a role of a nucleic acid drug, and the application prospect is broad. The targeting and effectiveness of treatment are effectively improved, and damage to normal brain tissues is avoided. A dual stimulation release mechanism of acid response and active oxygen response can accurately respond to glioma focuses and endogenous stimulation in cells. Through the synergistic compatibility of the G0-C14 carrier and the charge reversal polylysine, the loading efficiency of the YTHDF2 siRNA is effectively improved, and meanwhile, the cycling stability of the nucleic acid medicine in vivo is enhanced.

Provided in the present application is an anti-Siglec 15 antibody or an antigen-binding fragment thereof, a pharmaceutical composition and immunoconjugate comprising the antibody or antigen-binding fragment, a nucleic acid molecule encoding the antibody or antigen-binding fragment thereof, a vector comprising the nucleic acid molecule, a host cell comprising the vector, a method for preparing the antibody or antigen-binding fragment, and the biological medical use of the antibody or antigen-binding fragment. The use comprises regulating the immune response, reversing the inhibition of the Siglec15 protein on PBMC lymphocyte proliferation or treating tumors associated with abnormal Siglec 15 expression.

The present disclosure relates to methods of treating certain cancers with a Siglec-9 extracellular domain (ECD) or a Siglec-9 ECD fusion molecule, including cancers expressing high levels of CD163 and / or Siglec-9 in tumor or immune cells, and methods of identifying cancers responsive to a Siglec-9 ECD or Siglec-9 ECD fusion molecule, for example by determining the level of CD163 and / or Siglec-9, and in some embodiments also CD68 and / or sialic acid expression in tumor or immune cells.